Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Breast Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
48 drugs · 217 active trials
17 drugs · 330 active trials
43 drugs · 1,254 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Decitabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2001-12 |
| Imatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2005-05 |
| Selinexor | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jun 26, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Degarelix | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 28, 2019 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ibrutinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2015-03 |
| Immunotherapy | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2015-11 |
| Nilotinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Oct 13, 2022 |
| Obinutuzumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 27, 2018 |
| Pexidartinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 1, 2010 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 30, 2016 |
| Tivozanib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2012-11 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Belzutifan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 27, 2024 |
| Camonsertib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 13, 2023 |
| Immune Checkpoint Inhibitor | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 26, 2026 |
| Izorlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 24, 2023 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Lasofoxifene | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 1, 2010 |
| Lunresertib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 13, 2023 |
| Lutetium (177lu) Oxodotreotide | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 30, 2026 |
| Pacritinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 13, 2020 |
| Pertuzumab/Trastuzumab Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 1, 2010 |
| Rezatapopt | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 29, 2020 |
| Sotorasib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 7, 2023 |
| Telmisartan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-02 |
| Pemetrexed | Phase 2 | Phase 2 | 0 | 0 | 0 | 20 | 0 | — | — | 2000-12 |
| Irinotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 18 | 0 | — | — | 1998-08 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 12 | 0 | — | — | 2001-05 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2001-08 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 10 | 0 | — | — | Sep 15, 2009 |
| Panobinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2008-04 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | Jul 11, 2006 |
| Tipifarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2002-12 |
| Rucaparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2007-12 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2004-09 |
| Bosutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2008-04 |
| Ifosfamide | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 1997-03 |
| Poziotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2015-04 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | Aug 1, 2016 |
| Imiquimod | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2008-12 |
| Pictilisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2009-07 |
| Bexarotene | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1998-10 |
| Cabazitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2012-09 |
| Dactolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Dec 21, 2006 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2002-08 |
| Lonafarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2003-08 |
| Venetoclax | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Apr 14, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.